Literature DB >> 26825404

Pelvic Floor Disorders Registry: Study Design and Outcome Measures.

Emily Weber LeBrun1, Rony A Adam, Matthew D Barber, Sarah Hamilton Boyles, Cheryl B Iglesia, Emily S Lukacz, Pamela Moalli, Michael D Moen, Holly E Richter, Leslee L Subak, Vivian W Sung, Anthony G Visco, Catherine S Bradley.   

Abstract

Pelvic floor disorders affect up to 24% of adult women in the United States, and many patients with pelvic organ prolapse (POP) choose to undergo surgical repair to improve their quality of life. While a variety of surgical repair approaches and techniques are utilized, including mesh augmentation, there is limited comparative effectiveness and safety outcome data guiding best practice. In conjunction with device manufacturers, federal regulatory organizations, and professional societies, the American Urogynecologic Society developed the Pelvic Floor Disorders Registry (PFDR) designed to improve the quality of POP surgery by facilitating quality improvement and research on POP treatments. The PFDR will serve as a resource for surgeons interested in benchmarking and outcomes data and as a data repository for Food and Drug Administration-mandated POP surgical device studies. Provider-reported clinical data and patient-reported outcomes will be collected prospectively at baseline and for up to 3 years after treatment. All data elements including measures of success, adverse events, and surgeon characteristics were identified and defined within the context of the anticipated multifunctionality of the registry, and with collaboration from multiple stakeholders. The PFDR will provide a platform to collect high-quality, standardized patient-level data from a variety of nonsurgical (pessary) and surgical treatments of POP and other pelvic floor disorders. Data from this registry may be used to evaluate short- and longer-term treatment outcomes, patient-reported outcomes, and complications, as well as to identify factors associated with treatment success and failure with the overall goal of improving the quality of care for women with these conditions.

Entities:  

Mesh:

Year:  2016        PMID: 26825404     DOI: 10.1097/SPV.0000000000000237

Source DB:  PubMed          Journal:  Female Pelvic Med Reconstr Surg        ISSN: 2151-8378            Impact factor:   2.091


  6 in total

Review 1.  Mesh Perforation into a Viscus in the Setting of Pelvic Floor Surgery-Presentation and Management.

Authors:  Seth A Cohen; Howard B Goldman
Journal:  Curr Urol Rep       Date:  2016-09       Impact factor: 3.092

Review 2.  Outcomes collected in female pelvic floor surgical procedure registries and databases: a scoping review.

Authors:  Rasa Ruseckaite; Justin O Daly; Joanne Dean; Susannah Ahern
Journal:  Int Urogynecol J       Date:  2021-05-26       Impact factor: 2.894

3.  Generic Health-Related Quality of Life in Patients Seeking Care for Pelvic Organ Prolapse.

Authors:  Catherine S Bradley; Heidi W Brown; Stuart S Shippey; Robert E Gutman; Uduak U Andy; Ladin A Yurteri-Kaplan; Bela Kudish; Allen Mehr; Amy O'Boyle; Raymond T Foster; Jennifer T Anger; Patrick Ten Eyck; Pamela A Moalli
Journal:  Female Pelvic Med Reconstr Surg       Date:  2021-06-01       Impact factor: 1.913

4.  Landscape of Cardiovascular Device Registries in the United States.

Authors:  Prashant V Rajan; Jessica N Holtzman; Aaron S Kesselheim; Robert W Yeh; Daniel B Kramer
Journal:  J Am Heart Assoc       Date:  2019-06-01       Impact factor: 5.501

Review 5.  Patient-reported outcome measures for pain in women with pelvic floor disorders: a systematic review.

Authors:  Maisie Ralphsmith; Susannah Ahern; Joanne Dean; Rasa Ruseckaite
Journal:  Int Urogynecol J       Date:  2022-03-02       Impact factor: 1.932

6.  Evaluation of the acceptability of patient-reported outcome measures in women following pelvic floor procedures.

Authors:  Rasa Ruseckaite; Claire Bavor; Lucy Marsh; Joanne Dean; Oliver Daly; Dora Vasiliadis; Susannah Ahern
Journal:  Qual Life Res       Date:  2022-02-03       Impact factor: 3.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.